Which of the following cholinomimetics is commonly used in the treatment of glaucoma?
Rationale:
Pilocarpine is commonly used in the treatment of glaucoma. Pilocarpine, a muscarinic agonist, effectively reduces intraocular pressure by contracting the ciliary muscle, facilitating aqueous humor outflow through the trabecular meshwork. Its direct action on ocular muscarinic receptors makes it a preferred choice for managing glaucoma, improving fluid drainage and preventing optic nerve damage.
B: Locopperine lacks significant clinical application in glaucoma therapy as it does not demonstrate effective muscarinic receptor stimulation or notable intraocular pressure reduction, limiting its therapeutic relevance in ocular hypertension management.
C: Acetylcholine, despite being an endogenous cholinergic neurotransmitter, is rapidly degraded by cholinesterases and lacks practical use in glaucoma treatment due to poor pharmacokinetics and insufficient duration of action in the eye.
D: Neostigmine, a cholinesterase inhibitor, is primarily utilized for neuromuscular disorders and does not serve as a primary agent in glaucoma therapy, as it does not directly stimulate muscarinic receptors to enhance aqueous humor outflow.
All of the following parts of the heart are very sensitive to muscarinic receptor blockade except:
Rationale:
The ventricle is not very sensitive to muscarinic receptor blockade. Muscarinic receptors predominantly influence the atria, sinoatrial node, and atrioventricular node, where parasympathetic regulation significantly affects heart rate and conduction. Ventricular tissue has fewer muscarinic receptors, resulting in minimal direct parasympathetic impact, making it less responsive to muscarinic antagonism compared to other heart regions.
A: Atria Parasympathetic innervation richly targets the atria, making them highly responsive to muscarinic blockade, which modulates atrial contractility and heart rhythm through acetylcholine-sensitive receptors.
B: Sinoatrial node This pacemaker region is densely populated with muscarinic receptors, so blocking them alters heart rate by disrupting parasympathetic control, highlighting its strong sensitivity.
C: Atrioventricular node Muscarinic receptors regulate conduction velocity here; blockade impacts electrical transmission between atria and ventricles, demonstrating the node’s significant susceptibility to parasympathetic modulation.
Skeletal muscle relaxation and paralysis can occur from interruption of functions at several sites, including all of the following EXCEPT:
Rationale:
Skeletal muscle relaxation and paralysis do not occur from interruption of muscarinic acetylcholine receptors.
Muscarinic receptors primarily mediate parasympathetic effects in smooth muscles and glands, not skeletal muscle contraction. Skeletal muscles rely on nicotinic receptors at the motor end plate for neuromuscular transmission, so blocking muscarinic receptors does not directly affect skeletal muscle function or cause paralysis.
A: Nicotinic acetylcholine receptors are essential for neuromuscular transmission; their blockade prevents muscle contraction, causing paralysis.
C: The motor end plate is the site of acetylcholine release and receptor activation; disruption here impairs muscle excitation and contraction.
D: The contractile apparatus generates force in muscle fibers; its interruption directly halts contraction, resulting in muscle relaxation or paralysis.
Alphaâ‚ adrenoreceptors are located:
Rationale:
Alpha₁ adrenoreceptors are located postsynaptically in effector organs. These receptors primarily mediate the physiological responses to norepinephrine and epinephrine by causing vasoconstriction, smooth muscle contraction, and other actions in target tissues. Their postsynaptic location in effector organs allows direct modulation of cellular activity, influencing blood pressure and organ function through sympathetic nervous system activation.
B: Presynaptic alpha₁ adrenoreceptors are not typical; presynaptic receptors usually modulate neurotransmitter release and are predominantly alpha₂ types. Alpha₁ receptors mainly function postsynaptically, so this choice misattributes their anatomical and functional positioning within the nervous system.
C: Alpha₁ adrenoreceptors are sparse postsynaptically in the brain; central nervous system localization is mostly associated with other receptor subtypes. Their primary role is peripheral, controlling effector organ responses rather than direct central nervous system modulation.
D: Postsynaptic alpha₁ adrenoreceptors in the spinal cord are minimal; the spinal cord mainly contains interneurons and projection neurons. Alpha₁ receptors primarily target peripheral effector organs, not spinal cord neurons, making this location inaccurate.
Which of the following adverse effects is associated with administration of norepinephrine?
Rationale:
Norepinephrine administration is associated with arrhythmias. Norepinephrine primarily acts on alpha-1 and beta-1 adrenergic receptors, increasing heart rate and contractility, which can precipitate cardiac arrhythmias. Its potent vasoconstrictive effect elevates blood pressure, putting stress on the heart and disrupting normal electrical conduction, thereby increasing the risk of abnormal heart rhythms during treatment.
A: Bronchospasm Norepinephrine predominantly targets alpha and beta-1 receptors, not beta-2 receptors responsible for bronchodilation; therefore, it does not typically induce bronchospasm or constrict airway smooth muscle.
C: Decrease in blood pressure Norepinephrine causes vasoconstriction, leading to increased systemic vascular resistance and blood pressure, making a decrease in blood pressure unlikely following its administration.
D: Headache Although headaches can be side effects of many drugs, norepinephrine’s primary adverse effects relate to cardiovascular stress rather than causing headaches directly.
Which of the following sympathomimetics is related to short-acting topical decongestant agents?
Rationale:
Phenylephrine is related to short-acting topical decongestant agents. Phenylephrine acts primarily on alpha-1 adrenergic receptors causing vasoconstriction in nasal mucosa, effectively reducing swelling and congestion. Its short duration suits rapid relief in nasal decongestants. This characteristic distinguishes phenylephrine from longer-acting or systemic sympathomimetics used for other medical purposes such as bronchodilation or cardiovascular support.
A: Xylometazoline primarily serves as a long-acting nasal decongestant, not short-acting, producing prolonged vasoconstriction, which contrasts with phenylephrine’s brief duration suitable for quick relief.
B: Terbutaline functions mainly as a bronchodilator affecting beta-2 receptors, making it inappropriate for topical nasal decongestion, which largely depends on alpha-adrenergic receptor activation.
D: Norepinephrine is a potent systemic vasoconstrictor used in critical care for blood pressure support, lacking the short-acting topical application profile necessary for nasal decongestant use.
Therapeutic indications of dihydroergotamine include:
Rationale:
Dihydroergotamine is used therapeutically for the treatment of migraine. This medication acts as a vasoconstrictor and serotonin receptor agonist, effectively relieving migraine symptoms by constricting dilated cranial blood vessels and inhibiting the release of pro-inflammatory neuropeptides involved in migraine pathophysiology, making it a suitable and approved option for managing acute migraine attacks.
A: Hypertension Dihydroergotamine is not indicated for hypertension as its vasoconstrictive properties can potentially worsen high blood pressure rather than manage it, making it unsuitable for this condition’s treatment.
B: Pheochromocytoma This choice is inappropriate because dihydroergotamine does not address the excessive catecholamine secretion characteristic of pheochromocytoma, and its vasoconstrictive effects may exacerbate symptoms.
D: Raynaud’s phenomenon Dihydroergotamine’s vasoconstrictive mechanism contradicts the therapeutic goal for Raynaud’s phenomenon, which typically requires vasodilation to improve blood flow to extremities, rendering it ineffective here.
Indicate the drug, which has both alphaâ‚-selective and beta-blocking effects:
Rationale:
Labetalol has both alpha₁-selective and beta-blocking effects. Labetalol uniquely combines alpha₁-adrenergic receptor antagonism with non-selective beta-adrenergic blockade, resulting in vasodilation and decreased heart rate. This dual action makes it effective in treating hypertension and hypertensive emergencies, distinguishing it from beta-selective blockers that lack alpha₁ activity.
B: Betaxolol is a beta₁-selective blocker without alpha₁-adrenergic antagonism, focusing primarily on heart rate reduction without vasodilation through alpha blockade.
C: Propranolol is a non-selective beta-blocker lacking alpha₁-blocking effects, so it does not cause the vasodilation associated with alpha₁ receptor antagonism.
D: Timolol is a non-selective beta-blocker without alpha₁ receptor activity, limiting its action to beta-adrenergic blockade without affecting vascular alpha₁ receptors.
Indicate the hypnotic drug, which is long-acting:
Rationale:
Flurazepam is the hypnotic drug known for its long-acting properties. Flurazepam’s pharmacokinetics include a prolonged elimination half-life, leading to sustained sedative effects suitable for maintaining sleep. This extended duration differentiates it from shorter-acting hypnotics, making it preferable in cases where prolonged sleep induction and maintenance are desired without frequent dosing or rapid clearance.
A: Zaleplon has a very short half-life, resulting in brief sedative effects unsuitable for long-term sleep maintenance or lasting hypnotic action.
B: Triazolam’s short duration limits its use to sleep induction rather than sustained hypnotic effect throughout the night.
D: Zolpidem is intermediate-acting with a shorter half-life, providing rapid onset but insufficient duration for prolonged hypnotic activity.
The most effective drug for stopping generalized tonic-clonic status epilepticus in adults is:
Rationale:
Diazepam is the most effective drug for stopping generalized tonic-clonic status epilepticus in adults. Diazepam acts rapidly as a benzodiazepine enhancing GABAergic inhibition, providing quick seizure control crucial in emergency status epilepticus management. Its intravenous form is preferred for immediate intervention, effectively terminating seizures and preventing neuronal damage, unlike other options that are less suitable for acute generalized tonic-clonic seizures.
A: Lamotrigine is primarily used for long-term seizure control, not acute status epilepticus, and lacks rapid onset necessary for stopping ongoing generalized tonic-clonic seizures immediately.
B: Ethosuximide targets absence seizures specifically, showing minimal efficacy in controlling generalized tonic-clonic status epilepticus emergencies.
D: Zonisamide is an adjunctive therapy with slower action unsuitable for the urgent termination of generalized tonic-clonic status epilepticus episodes.
The mechanism of valproate action is:
Rationale:
Valproate acts through all of the mentioned mechanisms, including facilitation of glutamic acid decarboxylase, inhibition of GABA-aminotransferase, voltage-sensitive Na+ channel inhibition, and T-type Ca2+ channel blockade. This multifaceted action enhances GABA accumulation and stabilizes neuronal excitability, making option D the comprehensive choice that encompasses all these pharmacological effects of valproate.
A: Facilitation of glutamic acid decarboxylase and inhibition of GABA-aminotransferase explain only GABA-related effects, missing valproate’s role in blocking voltage-sensitive Na+ and T-type Ca2+ channels.
B: Inhibition of voltage sensitive Na+ channels accounts for reduced neuronal firing but excludes valproate’s enhancement of GABAergic activity and calcium channel inhibition.
C: Inhibition of low threshold (T-type) Ca2+ channels contributes to seizure control but does not represent the full spectrum of valproate’s mechanisms involving GABA metabolism and sodium channels.
Which of the following vitamins reduces the beneficial effects of levodopa by enhancing its extracerebral metabolism?
Rationale:
Pyridoxine reduces the beneficial effects of levodopa by enhancing its extracerebral metabolism.
Pyridoxine (vitamin B6) increases the peripheral decarboxylation of levodopa, which decreases the amount reaching the brain, thus diminishing its therapeutic effectiveness in Parkinson's disease. This interaction highlights why pyridoxine administration should be carefully managed or avoided during levodopa treatment to ensure optimal drug efficacy and symptom control.
B: Thiamine mainly supports carbohydrate metabolism and neurological function but does not influence levodopa metabolism or its therapeutic impact, making it unrelated to levodopa's extracerebral processing.
C: Tocopherol (vitamin E) acts as an antioxidant without affecting levodopa metabolism; it neither enhances nor reduces levodopa's bioavailability or efficacy in the peripheral tissues.
D: Riboflavin is crucial for energy production and enzyme function but lacks involvement in levodopa metabolism, thus not altering levodopa’s pharmacokinetics or therapeutic outcomes.
Which of the following drugs antagonizes the effects of levodopa because it leads to a junctional blockade of dopamine action?
Rationale:
Haloperidol antagonizes the effects of levodopa by causing a junctional blockade of dopamine action. Haloperidol is a dopamine receptor antagonist that directly blocks dopamine receptors, preventing dopamine from exerting its effects despite increased dopamine levels from levodopa. This receptor-level inhibition effectively counters levodopa’s therapeutic action in conditions like Parkinson’s disease.
A: Reserpine depletes dopamine stores by inhibiting vesicular monoamine transporters but does not cause a direct junctional blockade of dopamine receptors, differing fundamentally from levodopa antagonism.
C: Chlorpromazine, a dopamine antagonist, blocks dopamine receptors but has broader receptor activity and is less specific in causing junctional dopamine blockade compared to haloperidol’s potent receptor antagonism.
D: All of the above incorrectly suggests resperine and chlorpromazine share the exact dopamine receptor blockade mechanism, while only haloperidol directly causes junctional dopamine receptor antagonism.
The principal central nervous system effect of the opioid analgesics with affinity for a mu receptor is:
Rationale:
Analgesia is the principal central nervous system effect of opioid analgesics with affinity for the mu receptor. These opioids primarily bind to mu receptors in the brain and spinal cord, inhibiting pain transmission and perception, which results in effective pain relief. While other effects occur, analgesia remains the most significant therapeutic action in clinical use.
B: Respiratory depression occurs with mu opioids but is a serious side effect, not the primary therapeutic effect, and is less desirable than analgesia for clinical pain management.
C: Euphoria is a secondary effect that may contribute to abuse potential but is not the main intended central nervous system outcome of mu opioid receptor activation.
D: All of the above suggests equal central importance, but analgesia is the foremost desired effect, while respiratory depression and euphoria are side effects or secondary outcomes.
Which of the following non-narcotic agents is salicylic acid derivative?
Rationale:
Aspirin is the salicylic acid derivative among the listed non-narcotic agents. Aspirin, chemically known as acetylsalicylic acid, originates from salicylic acid and exhibits anti-inflammatory, analgesic, and antipyretic properties. It functions by inhibiting cyclooxygenase enzymes, reducing prostaglandin synthesis. This distinctive mechanism and chemical structure classify aspirin as a salicylic acid derivative, unlike the other options.
A: Phenylbutazone Phenylbutazone is a nonsteroidal anti-inflammatory drug but belongs to the pyrazolidinedione class, not related to salicylic acid structure or derivatives, differentiating it from aspirin’s chemical family.
B: Ketamine Ketamine is an anesthetic agent with NMDA receptor antagonist properties, unrelated to salicylic acid derivatives, focusing on dissociative anesthesia rather than anti-inflammatory effects typical of salicylic compounds.
D: Tramadol Tramadol is a synthetic opioid analgesic acting on central nervous system receptors, distinct chemically and functionally from salicylic acid derivatives like aspirin, which primarily target inflammatory pathways.
Tardive dyskinesia is the result of:
Rationale:
Tardive dyskinesia is the result of a hyperactive dopaminergic state in the presence of dopamine blockers.
This condition arises when chronic dopamine receptor blockade, especially in the nigrostriatal pathway, causes upregulation and hypersensitivity of dopamine receptors. The increased dopaminergic activity despite antagonism leads to involuntary, repetitive movements characteristic of tardive dyskinesia, linking the disorder directly to altered dopamine receptor dynamics under dopamine blocker influence.
A: Degeneration of dopaminergic and cholinergic fibers involves neuronal loss, which does not primarily cause tardive dyskinesia’s hallmark receptor hypersensitivity or involuntary movements.
C: Degeneration of histaminergic fibers is unrelated to tardive dyskinesia, as histamine pathways do not significantly contribute to the disorder’s dopaminergic receptor supersensitivity or motor symptoms.
D: Supersensitivity of cholinergic receptors in the caudate-putamen does not explain tardive dyskinesia, which is mainly driven by dopaminergic receptor changes, not cholinergic receptor alterations.
Which of the following statements is correct for lithium?
Rationale:
Lithium decreases catecholamine-related activity. This is accurate because lithium modulates neurotransmitter systems by reducing catecholamine signaling, which contributes to its mood-stabilizing effects in conditions like bipolar disorder. By dampening excessive catecholamine activity, lithium helps restore neurotransmitter balance, preventing manic and depressive episodes, aligning precisely with its pharmacological profile and therapeutic action.
A: Stimulate dopamine and beta-adrenergic receptors incorrectly attributes an activating effect to lithium, whereas lithium actually inhibits or modulates these receptors, reducing overactivity rather than stimulating them.
C: Stimulate the development of dopamine receptor supersensitivity inaccurately suggests lithium increases receptor sensitivity, but lithium typically normalizes receptor function instead of causing supersensitivity.
D: Decrease cholinergic activity wrongly implies lithium suppresses cholinergic neurotransmission, which is not a primary effect of lithium’s mechanism of action on neurotransmitter systems.
Fluoxetine has fewer adverse effects because of:
Rationale:
Fluoxetine has fewer adverse effects because of minimal binding to cholinergic, histaminic, and alfa-adrenergic receptors. This selective receptor profile reduces side effects commonly linked to these receptor interactions, such as dry mouth, sedation, and orthostatic hypotension, making fluoxetine better tolerated compared to drugs with broader receptor activity and multiple neurotransmitter system involvement.
A: Mixed norepinephrine and serotonin reuptake inhibition increases the potential for side effects due to broader neurotransmitter impact, unlike fluoxetine’s selective receptor binding minimizing adverse reactions.
B: Depleted stores of amine neurotransmitters lead to decreased neurotransmission and are not related to fluoxetine’s mechanism or side effect profile.
D: All of the above incorrectly combines unrelated mechanisms; fluoxetine’s fewer adverse effects stem specifically from minimal receptor binding, not from all listed factors.
Indicate the mechanism of hypnotic benzodiazepine action:
Rationale:
Hypnotic benzodiazepines act by increasing the frequency of Cl- channel opening events. This enhances GABAergic inhibitory neurotransmission by promoting more frequent chloride ion influx, leading to neuronal hyperpolarization and reduced excitability. Unlike barbiturates, which increase channel open duration, benzodiazepines specifically augment the frequency, thereby potentiating GABA’s natural inhibitory effect without directly opening the channel.
A: Increasing the duration of the GABA-gated Cl- channel openings reflects barbiturate action, not benzodiazepines, which modulate frequency rather than channel open time.
B: Directly activating the chloride channels describes a mechanism absent in benzodiazepines; they require GABA presence to exert their modulatory effect.
D: All of the above combines incompatible mechanisms; benzodiazepines specifically increase frequency only, not duration or direct channel activation.
Adaptogens cause:
Rationale:
Adaptogens cause increased resistance towards stress situations and adaptation to extreme conditions. Adaptogens enhance the body's ability to maintain homeostasis by regulating physiological processes, thus improving resilience to stress and promoting adaptation to harsh environments. This effect helps organisms better cope with external stressors without exhausting their resources, making option D the most comprehensive and accurate description of adaptogens’ primary function.
A: Improvement of efficiency using physical loads and acceleration of recovery after the load focuses solely on physical performance and recovery, which is a narrower effect than the broad stress resistance and adaptation provided by adaptogens.
B: Stimulation of respiratory and vasomotor centers describes a specific physiological activation unrelated to the holistic stress resilience and adaptive capacity characteristic of adaptogens.
C: Temporary relief of the feeling of tiredness, facilitating the professional work and fighting somnolence addresses short-term fatigue relief rather than the sustained enhancement of stress resistance and environmental adaptation.
Piracetam is widely used for the treatment of:
Rationale:
Piracetam is widely used for the treatment of all of the above conditions. Piracetam enhances cognitive function and neuroprotection, making it effective for senile dementia, asthenia, and chronic alcoholism by improving brain metabolism, circulation, and neurotransmission. Its versatile pharmacological profile supports multiple neurological and cognitive disorders, justifying its broad therapeutic application across these diverse ailments.
A: Senile dementia only targets one condition, whereas Piracetam treats multiple neurological issues, so this option is too limited and does not encompass its full therapeutic range.
B: Asthenia refers to weakness, but Piracetam's benefits extend beyond this symptom to cognitive and neurological disorders, making this choice incomplete.
C: Chronic alcoholism is addressed by Piracetam, but the drug’s efficacy also includes dementia and asthenia, so focusing solely on alcoholism is restrictive.
LSD produces:
Rationale:
LSD produces all of the above effects. LSD is known for causing a range of psychological and cognitive effects including mood swings, impaired memory, difficulty in thinking, poor judgment, and significant perceptual distortions. These combined effects contribute to its classification as a powerful hallucinogen that affects multiple aspects of mental functioning and perception simultaneously.
A: Mood swings only represent a partial effect of LSD, neglecting important cognitive impairments and sensory distortions that are also prominent.
B: Impaired memory, difficulty in thinking, poor judgment describe some effects but omit mood changes and perceptual alterations fundamental to LSD’s impact.
C: Perceptual distortion highlights a key LSD effect but excludes mood fluctuations and cognitive deficits that comprehensively characterize its influence.
Indicated the inhaled anesthetic, which may cause nephrotoxicity:
Rationale:
Sevoflurane may cause nephrotoxicity due to its metabolite fluoride ions.
Sevoflurane undergoes hepatic metabolism producing inorganic fluoride, which can induce renal tubular damage leading to nephrotoxicity. Its extensive metabolism compared to other anesthetics increases fluoride levels, posing a risk to kidney function, especially in prolonged exposures or compromised renal conditions. This distinct metabolic pathway differentiates it from other inhaled agents with minimal nephrotoxic potential.
A: Halothane lacks significant nephrotoxic metabolites; its primary risks involve hepatotoxicity, not renal damage, making it an unlikely cause of nephrotoxicity.
C: Nitrous oxide is minimally metabolized and does not generate nephrotoxic compounds, thus presenting negligible risk to renal function.
D: Diethyl ether’s metabolism is limited and does not produce nephrotoxic substances, focusing more on respiratory irritation rather than kidney toxicity.
The property of prolonged theophyllines is the prevention of night asthmatic attacks. It’s:
Rationale:
Prolonged theophyllines effectively prevent night asthmatic attacks by maintaining bronchodilation and reducing airway inflammation throughout the night.
This option is accurate because prolonged theophyllines provide sustained anti-inflammatory and bronchodilator effects, which help control nocturnal asthma symptoms and decrease the frequency of night attacks, improving respiratory function during sleep.
B: FALSE denies the established benefit of prolonged theophyllines in preventing nocturnal asthma, contradicting evidence-based therapeutic effects.
C: None does not address the question, offering no relevant information about theophylline’s role in nocturnal asthma management.
D: All of the above illogically groups true and false statements together, causing confusion and misrepresenting theophylline’s proven properties.
Choose the drug that causes constipation:
Rationale:
Aluminium hydroxide causes constipation. Aluminium hydroxide acts as an antacid that neutralizes stomach acid but often leads to reduced gastrointestinal motility, resulting in constipation. It binds phosphate in the gut and has a drying effect on stools, slowing bowel movements and causing hard, difficult-to-pass stools. This side effect distinguishes it from other antacids with different gastrointestinal profiles.
A: Sodium bicarbonate primarily causes belching and metabolic alkalosis rather than constipation, as it rapidly neutralizes acid without significantly altering bowel motility or stool consistency.
C: Calcium carbonate may cause mild constipation but more commonly leads to acid rebound and kidney stones, lacking the pronounced constipating effect seen with aluminium hydroxide.
D: Magnesium oxide typically causes diarrhea or soft stools by drawing water into the intestines, which contrasts with the constipating influence of aluminium compounds.
The drugs used for oral administration EXCLUDE:
Rationale:
The drugs used for oral administration exclude Fercoven. Fercoven is typically administered via parenteral routes rather than orally, distinguishing it from ferrous sulfate, ferrous lactate, and ferrous fumarate, which are all common oral iron supplements. This difference in administration route is essential for ensuring proper absorption and therapeutic effect in treating iron deficiency.
A: Ferrous sulfate is a widely used oral iron supplement, known for its efficacy and bioavailability, making it suitable for oral administration in treating iron deficiency anemia.
C: Ferrous lactate is an oral iron compound, easily absorbed through the gastrointestinal tract, commonly prescribed for oral supplementation to correct iron deficiency.
D: Ferrous fumarate is another oral iron medication, favored for its high iron content and effectiveness when administered orally to improve hemoglobin levels.
Fibrinolytic drugs are used for following EXCEPT:
Rationale:
Fibrinolytic drugs are not used for heart failure.
This is because fibrinolytic drugs target blood clots by dissolving fibrin, making them effective in treating conditions caused by thrombosis, such as deep venous thrombosis, pulmonary emboli, and acute myocardial infarction, but heart failure results from cardiac dysfunction rather than clot formation, so fibrinolytics have no therapeutic role in its management.
A: Central deep venous thrombosis Fibrinolytics effectively dissolve clots in deep veins, restoring blood flow and preventing complications, which suits this condition’s thrombotic nature.
B: Multiple pulmonary emboli These drugs rapidly break down emboli blocking pulmonary arteries, reducing mortality and improving oxygenation, aligning perfectly with their clot-busting action.
D: Acute myocardial infarction Fibrinolytics restore coronary artery patency by lysing thrombi, minimizing heart muscle damage, a primary indication for their use in acute myocardial infarction therapy.
This drug is useful for treating heart failure because it increases the inotropic state and reduces afterload:
Rationale:
Amrinone is useful for treating heart failure because it increases the inotropic state and reduces afterload. Amrinone is a phosphodiesterase inhibitor that enhances myocardial contractility by raising intracellular cAMP and promotes vasodilation, thereby decreasing systemic vascular resistance. This dual action improves cardiac output and reduces the heart's workload, making it effective in managing heart failure symptoms.
A: Amiodarone primarily treats arrhythmias and does not significantly improve contractility or reduce afterload; its effects focus on stabilizing cardiac rhythm rather than enhancing inotropic state or vascular dynamics.
C: Propranolol is a beta-blocker that decreases heart rate and contractility, which can worsen heart failure by lowering inotropic state and does not reduce afterload.
D: Enalapril is an ACE inhibitor that reduces afterload but does not directly increase inotropic state, so it lacks the combined effect necessary for this specific heart failure treatment.
This drug has a little or no direct effect on chronotropy and dromotropy at normal doses:
Rationale:
Nifedipine has little or no direct effect on chronotropy and dromotropy at normal doses. Nifedipine primarily acts as a vascular selective calcium channel blocker, causing vasodilation without significantly affecting heart rate or atrioventricular conduction. It contrasts with other calcium channel blockers that influence cardiac electrical activity, making it unique in its minimal impact on chronotropic and dromotropic functions at therapeutic levels.
B: Diltiazem significantly affects both heart rate and AV nodal conduction, altering chronotropy and dromotropy; it acts on cardiac muscle and nodal tissue unlike nifedipine’s vascular selectivity.
C: Verapamil strongly influences chronotropy and dromotropy by depressing sinoatrial and atrioventricular nodes, causing negative chronotropic and dromotropic effects, which is unlike nifedipine’s minimal cardiac impact.
D: All of the above inaccurately groups drugs with differing cardiac effects; nifedipine’s lack of direct chronotropic and dromotropic influence contrasts with verapamil and diltiazem’s notable actions.
All of the following statements regarding vasodilators are true EXCEPT:
Rationale:
Nifedipine is a dopamine receptor antagonist. Nifedipine is actually a calcium channel blocker used primarily for hypertension and angina by relaxing vascular smooth muscle, not a dopamine receptor antagonist. This misclassification makes option B false, as it inaccurately describes nifedipine’s pharmacological action, unlike the other statements which accurately reflect the properties and side effects of their respective vasodilators.
A: Hydralazine causes tachycardia. Hydralazine induces reflex tachycardia due to peripheral vasodilation lowering blood pressure, which triggers sympathetic nervous system activation to maintain cardiac output.
C: Nitroprusside dilates both arterioles and veins. Nitroprusside acts as a balanced vasodilator affecting both arterial and venous smooth muscle, reducing preload and afterload effectively in hypertensive emergencies.
D: Minoxidil can cause hypertrichosis. Minoxidil’s side effect includes promoting hair growth (hypertrichosis) by enhancing follicular blood flow and stimulating hair follicles, a well-documented clinical observation.